CMS released the Calendar Year 2027 Part D national average monthly bid amount on July 28, 2026, alongside a fact sheet detailing the base beneficiary premium projected at $41.33 per month for 2027, according to the Medicare Trustees Report (Kiplinger). The figure marks a notable increase from 2026 levels, when the average stand-alone Part D prescription drug plan (PDP) premium stood at $36, down from $39 the prior year (KFF).

The premium trajectory shift is driven partly by spending on high-cost medications, including GLP-1 receptor agonists, according to a MarketWatch report published July 29, 2026 (MarketWatch). A Wall Street Journal report dated July 28, 2026, referenced by MarketWatch, similarly flagged that Part D premiums are set to increase sharply.

The Inflation Reduction Act of 2022 restructured the Medicare Part D benefit substantially, directing CMS to phase in changes through 2026. The out-of-pocket spending cap, which dropped to $2,000 in 2025, rose to $2,100 in 2026, a 5% increase reflecting an indexed adjustment mechanism rather than a policy reversal (AARP). The maximum Part D deductible also moved from $590 in 2025 to $615 in 2026. CMS has characterized the Medicare Advantage and Medicare Prescription Drug Programs as expected to remain stable in 2026 (CMS).

The structural redesign carries fiscal consequences for plans and taxpayers. CMS finalized updates to the Part D risk adjustment model in the CY 2027 Medicare Advantage and Part D Rate Announcement to reflect IRA-driven benefit changes (CMS). The agency also published the Contract Year 2027 Medicare Advantage and Part D Final Rule on April 2, 2026, which codifies operational parameters for benefit implementation (CMS). Under the CY 2027 Rate Announcement, CMS projects a 2.48% increase in payments to Medicare Advantage plans, totaling over $13 billion (CMS).

Enrollment dynamics add another layer. More than half of eligible Medicare beneficiaries, 55%, are enrolled in Medicare Advantage in 2026 (KFF). Humana gained the most Medicare Advantage enrollees overall among all Medicare insurers for the year (KFF). On the Part D side, beneficiaries have between 8 and 12 stand-alone PDP options for 2026 (KFF), with several national stand-alone plans charging premiums well below $10 per month in many regions (KFF). The average MA-PD premium, meanwhile, increased modestly from $7 the prior year (KFF).

The premium suppression visible in 2026 PDP pricing was not purely organic. Medicare Advantage plans receive rebate dollars from Medicare, a dynamic that has historically distorted the relationship between bid amounts and what beneficiaries actually pay (MarketWatch). The $41.33 base beneficiary premium figure for 2027, drawn from the Trustees Report, reflects the national average monthly bid amount before premium subsidies and reinsurance are applied. It is the benchmark against which the Part D "premium stabilization" mechanism operates, capping year-over-year increases for the base premium.

The broader context here is a benefit in structural transition. The IRA eliminated the catastrophic phase cost-sharing for plans in 2024, shifted manufacturer discount responsibility, and established the $2,000 out-of-pocket cap in 2025. Those changes re-priced plan liability across the benefit phases. With the out-of-pocket cap now indexing upward to $2,100, and with GLP-1 utilization placing material pressure on drug spend, plan bids for 2027 reflect the cost of a redesigned benefit that the 2026 bid cycle only partially captured. The jump from a $36 average PDP premium in 2026 to a projected $41.33 base beneficiary premium in 2027 quantifies that adjustment, though the two figures are not strictly comparable: one is an observed average of stand-alone PDP premiums, the other a Trustees Report projection of the base beneficiary premium derived from the national average monthly bid.

For stakeholders, the signal is that the IRA's cost-shifting from beneficiaries to plans and manufacturers is now flowing through to premiums. The 2026 premium compression, driven by aggressive bidding under the new benefit structure, appears to have been a transitional effect. The 2027 figures suggest convergence toward a higher equilibrium.